This HTML5 document contains 193 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/chebi/
n10http://linked.opendata.cz/resource/drugbank/mixture/
n26http://www.drugs.com/
n20http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/wikipedia/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n36http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/pdb/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/patent/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/bindingdb/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n34http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/property/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/drugbank/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/iuphar/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/guide-to-pharmacology/
n9http://linked.opendata.cz/resource/atc/
n35http://linked.opendata.cz/resource/drugbank/drug/DB00627/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00627
rdf:type
n3:Drug
n3:description
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem]
n3:dosage
n5:271B5B00-363D-11E5-9242-09173F13E4C5 n5:271B5B01-363D-11E5-9242-09173F13E4C5 n5:271B5B02-363D-11E5-9242-09173F13E4C5 n5:271B5B03-363D-11E5-9242-09173F13E4C5 n5:271B5AFD-363D-11E5-9242-09173F13E4C5 n5:271B5AFE-363D-11E5-9242-09173F13E4C5 n5:271B5AFF-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15651982
n3:group
investigational nutraceutical approved
n3:halfLife
20-45 minutes.
n3:indication
For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
n3:manufacturer
n7:271B5AD2-363D-11E5-9242-09173F13E4C5 n7:271B5AD3-363D-11E5-9242-09173F13E4C5 n7:271B5AD0-363D-11E5-9242-09173F13E4C5 n7:271B5AD1-363D-11E5-9242-09173F13E4C5 n7:271B5AD6-363D-11E5-9242-09173F13E4C5 n7:271B5AD7-363D-11E5-9242-09173F13E4C5 n7:271B5AD4-363D-11E5-9242-09173F13E4C5 n7:271B5AD5-363D-11E5-9242-09173F13E4C5 n7:271B5ACE-363D-11E5-9242-09173F13E4C5 n7:271B5ACF-363D-11E5-9242-09173F13E4C5 n7:271B5ACC-363D-11E5-9242-09173F13E4C5 n7:271B5ACD-363D-11E5-9242-09173F13E4C5 n7:271B5ADA-363D-11E5-9242-09173F13E4C5 n7:271B5ADB-363D-11E5-9242-09173F13E4C5 n7:271B5AD8-363D-11E5-9242-09173F13E4C5 n7:271B5AD9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00627 n20:DB00627
dcterms:title
Niacin
adms:identifier
n22:23515 n23:DB00627 n24:15940 n25:913 n27:Niacin n28:46507508 n29:C00253 n30:D00049 n31:1594 n32:1594 n33:PA450617 n34:938 n35:0245-0067-11 n36:NIO
n3:mechanismOfAction
Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.
n3:packager
n7:271B5ABE-363D-11E5-9242-09173F13E4C5 n7:271B5ABF-363D-11E5-9242-09173F13E4C5 n7:271B5ABD-363D-11E5-9242-09173F13E4C5 n7:271B5AC6-363D-11E5-9242-09173F13E4C5 n7:271B5AC7-363D-11E5-9242-09173F13E4C5 n7:271B5AC4-363D-11E5-9242-09173F13E4C5 n7:271B5AC5-363D-11E5-9242-09173F13E4C5 n7:271B5AC2-363D-11E5-9242-09173F13E4C5 n7:271B5AC3-363D-11E5-9242-09173F13E4C5 n7:271B5AC0-363D-11E5-9242-09173F13E4C5 n7:271B5AC1-363D-11E5-9242-09173F13E4C5 n7:271B5ACA-363D-11E5-9242-09173F13E4C5 n7:271B5ACB-363D-11E5-9242-09173F13E4C5 n7:271B5AC8-363D-11E5-9242-09173F13E4C5 n7:271B5AC9-363D-11E5-9242-09173F13E4C5 n7:271B5ABB-363D-11E5-9242-09173F13E4C5 n7:271B5ABC-363D-11E5-9242-09173F13E4C5 n7:271B5AB1-363D-11E5-9242-09173F13E4C5 n7:271B5AB2-363D-11E5-9242-09173F13E4C5 n7:271B5AB9-363D-11E5-9242-09173F13E4C5 n7:271B5ABA-363D-11E5-9242-09173F13E4C5 n7:271B5AB7-363D-11E5-9242-09173F13E4C5 n7:271B5AB8-363D-11E5-9242-09173F13E4C5 n7:271B5AB5-363D-11E5-9242-09173F13E4C5 n7:271B5AB6-363D-11E5-9242-09173F13E4C5 n7:271B5AB3-363D-11E5-9242-09173F13E4C5 n7:271B5AB4-363D-11E5-9242-09173F13E4C5
n3:patent
n16:6129930 n16:2298549 n16:6469035 n16:2283159
n3:synonym
Vitamin B3 Nikotinsaeure Nicotinic Acid beta-Pyridinecarboxylic acid Acidum Nicotinicum PP Factor 3-Pyridylcarboxylic acid Acido nicotinico Pellagra preventive factor Niacin pyridine-β-carboxylic acid Pyridine-beta-carboxylic acid Anti-pellagra vitamin 3-carboxypyridine β-pyridinecarboxylic acid Acide Nicotinique 3-Pyridinecarboxylic acid P.P. factor M-Pyridinecarboxylic Acid
n3:toxicity
Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD<sub>50</sub> 7000 mg/kg (Rat)
n8:hasAHFSCode
n19:24-06-92 n19:88-08-00
n3:foodInteraction
Avoid alcohol. Take with food.
n3:mixture
n10:271B5AAE-363D-11E5-9242-09173F13E4C5 n10:271B5AAF-363D-11E5-9242-09173F13E4C5 n10:271B5AAC-363D-11E5-9242-09173F13E4C5 n10:271B5AAD-363D-11E5-9242-09173F13E4C5 n10:271B5AB0-363D-11E5-9242-09173F13E4C5 n10:271B5AA6-363D-11E5-9242-09173F13E4C5 n10:271B5AA7-363D-11E5-9242-09173F13E4C5 n10:271B5AA4-363D-11E5-9242-09173F13E4C5 n10:271B5AA5-363D-11E5-9242-09173F13E4C5 n10:271B5AAA-363D-11E5-9242-09173F13E4C5 n10:271B5AAB-363D-11E5-9242-09173F13E4C5 n10:271B5AA8-363D-11E5-9242-09173F13E4C5 n10:271B5AA9-363D-11E5-9242-09173F13E4C5 n10:271B5AA2-363D-11E5-9242-09173F13E4C5 n10:271B5AA3-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Joseph E. Toomey, Jr., "Electrochemical synthesis of niacin and other N-heterocyclic compounds." U.S. Patent US5002641, issued 1914.
n17:hasConcept
n18:M0014807
foaf:page
n14:niacor.htm n26:niacin.html
n3:IUPAC-Name
n6:271B5B08-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5B0E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5B0D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5B0A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5B0B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5B0C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5B1E-363D-11E5-9242-09173F13E4C5 n6:271B5B06-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5B07-363D-11E5-9242-09173F13E4C5 n6:271B5B20-363D-11E5-9242-09173F13E4C5 n6:271B5B04-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5B21-363D-11E5-9242-09173F13E4C5 n6:271B5B05-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B5B22-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:C04AC01 n9:C10AD02
n3:H-Bond-Acceptor-Count
n6:271B5B14-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5B15-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5B0F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5B10-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5B12-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5B11-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5B13-363D-11E5-9242-09173F13E4C5
n3:absorption
Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59-67-6
n3:category
n3:containedIn
n4:271B5ADC-363D-11E5-9242-09173F13E4C5 n4:271B5AE9-363D-11E5-9242-09173F13E4C5 n4:271B5AEA-363D-11E5-9242-09173F13E4C5 n4:271B5AE7-363D-11E5-9242-09173F13E4C5 n4:271B5AE8-363D-11E5-9242-09173F13E4C5 n4:271B5AE5-363D-11E5-9242-09173F13E4C5 n4:271B5AE6-363D-11E5-9242-09173F13E4C5 n4:271B5AE3-363D-11E5-9242-09173F13E4C5 n4:271B5AE4-363D-11E5-9242-09173F13E4C5 n4:271B5AF1-363D-11E5-9242-09173F13E4C5 n4:271B5AF2-363D-11E5-9242-09173F13E4C5 n4:271B5AEF-363D-11E5-9242-09173F13E4C5 n4:271B5AF0-363D-11E5-9242-09173F13E4C5 n4:271B5AED-363D-11E5-9242-09173F13E4C5 n4:271B5AEE-363D-11E5-9242-09173F13E4C5 n4:271B5AEB-363D-11E5-9242-09173F13E4C5 n4:271B5AEC-363D-11E5-9242-09173F13E4C5 n4:271B5AF9-363D-11E5-9242-09173F13E4C5 n4:271B5AFA-363D-11E5-9242-09173F13E4C5 n4:271B5AF7-363D-11E5-9242-09173F13E4C5 n4:271B5AF8-363D-11E5-9242-09173F13E4C5 n4:271B5AF5-363D-11E5-9242-09173F13E4C5 n4:271B5AF6-363D-11E5-9242-09173F13E4C5 n4:271B5AF3-363D-11E5-9242-09173F13E4C5 n4:271B5AF4-363D-11E5-9242-09173F13E4C5 n4:271B5AFB-363D-11E5-9242-09173F13E4C5 n4:271B5AFC-363D-11E5-9242-09173F13E4C5 n4:271B5AE1-363D-11E5-9242-09173F13E4C5 n4:271B5AE2-363D-11E5-9242-09173F13E4C5 n4:271B5ADF-363D-11E5-9242-09173F13E4C5 n4:271B5AE0-363D-11E5-9242-09173F13E4C5 n4:271B5ADD-363D-11E5-9242-09173F13E4C5 n4:271B5ADE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5B1A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5B1C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5B1D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5B1F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5B19-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5B18-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5B1B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5B09-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5B16-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5B17-363D-11E5-9242-09173F13E4C5